



Agreements

1 August 2007

Biomedical Business & Technology

* Third Wave Technologies (Madison, Wisconsin) reported that it has signed a pharmacogenetics collaboration with Laboratory Corporation of America Holdings (LabCorp; Burlington, North Carolina) to develop a companion diagnostic to help physicians personalize treatment for heart failure patients. The test is being developed with Third wave's Invader chemistry in conjunction with the prescription of bucindolol, a next-generation beta blocker being developed by **ARCA Discovery** (Denver, Colorado).

SOURCE-Biomedical Business & Technology

COPYRIGHT 2007 AHC Media LLC